Current opinion in ophthalmology
-
Curr Opin Ophthalmol · Apr 2004
Review Randomized Controlled Trial Clinical TrialFactors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.
This review summarizes factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of treatment. EMGT randomized patients with early glaucoma either to argon laser trabeculoplasty plus betaxolol (n = 129) or to no immediate treatment (n = 126) and followed them every 3 months. ⋯ EMGT treatment reduced progression risk in half, demonstrating the value of IOP lowering in early glaucoma. Age and indicators of disease severity also predicted progression.